43091-72-1

Basic information

• Product Name: 1-(2-METHOXYPHENYL)-4-(2-CHLOROETHYL)PIPERAZINE DIHYDROCHLORIDE
• Synonyms: methoxyphenylchloroetylpiperazinedihydrochloride;1-(2-METHOXYPHENYL)-4-(2-CHLOROETHYL)PIPERAZINE DIHYDROCHLORIDE;4-(2-CHLOROETHYL)-1-(2-METHOXYPHENYL)PIPERAZINE DIHYDROCHLORIDE;1-(2-Chloroethyl)-4-(2-methoxyphenyl)piperazine2HCl;4-(2-Chloroethyl)-1-(2-methoxyphenyl)piperazine dihydrochloride 98%;1-(2-Methoxyphenyl)-4-(2-chloroethyl)piperazine;1-(2-Methoxyphenyl)-4-(2-chlorethyl)-piperazin.2HCI;1-(2-chloroethyl)-4-(2-methoxyphenyl)piperazine
• CAS NO: 43091-72-1
• Molecular Formula: C₁₃H₁₉ClN₂O
• Molecular Weight: 327.68
• Mol File: 43091-72-1.mol
• Article Data: 14

Chemical Properties

• Melting Point: 240 °C
• Boiling Point: 374 °C at 760 mmHg
• Flash Point: 180 °C
• Appearance: /
• Density: 1.128±0.06 g/cm3(Predicted)
• PKA: 6.65±0.40(Predicted)
• CAS DataBase Reference: 1-(2-METHOXYPHENYL)-4-(2-CHLOROETHYL)PIPERAZINE DIHYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-METHOXYPHENYL)-4-(2-CHLOROETHYL)PIPERAZINE DIHYDROCHLORIDE(43091-72-1)
• EPA Substance Registry System: 1-(2-METHOXYPHENYL)-4-(2-CHLOROETHYL)PIPERAZINE DIHYDROCHLORIDE(43091-72-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 43091-72-1(Hazardous Substances Data)

Usage

General Description

1-(2-Methoxyphenyl)-4-(2-chloroethyl)piperazine dihydrochloride is a chemical compound that contains a piperazine ring with a 2-methoxyphenyl group and a 2-chloroethyl group attached. It is commonly used as a pharmaceutical intermediate and research compound in the development of potential drugs for various medical conditions. 1-(2-METHOXYPHENYL)-4-(2-CHLOROETHYL)PIPERAZINE DIHYDROCHLORIDE has been studied for its potential as an antipsychotic and anxiolytic agent and has also been investigated for its potential in cancer treatment due to its ability to inhibit cell growth. The dihydrochloride form of the compound allows for greater stability and solubility, making it a preferred form for pharmaceutical and research applications.

Upstream product

• 35386-24-4 1-(2-Methoxyphenyl)piperazine 
• 107-04-0 1-Bromo-2-chloroethane 
• 5464-78-8 1-(2-methoxyphenyl)piperazine hydrochloride 
• 90-04-0 2-methoxy-phenylamine 
• 21057-39-6 2-chloro-1-[4-(2-methoxyphenyl)-1-piperazinyl]ethan-1-one 
• 80-41-1 2-chloroethyl tosylate 

Downstream Products

• 155204-28-7 1-(2-methoxyphenyl)-4-(2-(2-pyridylamino)ethyl)piperazine 
• 1065585-97-8 2-(furan-2-yl)-7-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)-7H-pyrrolo[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine 
• 1092766-55-6 2-{2-[2-(3-methoxyphenyl)ethyl]phenoxy}ethyl-4-(2'-methoxyphenyl)piperazine 
• 1334582-04-5 C₂₁H₂₅N₅O 
• 1334582-14-7 C₂₁H₂₅N₅O 
• 81513-97-5 3-{2-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-ethyl}-3H-benzooxazol-2-one 
• 134337-01-2 3-<2-<4-(2-methoxyphenyl)-1-piperazinyl>ethyl>oxazolo<4,5-b>pyridin-2(3H)-one 

Relevant articles and documents

Design, synthesis, and biological evaluation of arylpiperazine-benzylpiperidines with dual serotonin and norepinephrine reuptake inhibitory activities

The limitations of established serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) reuptake inhibitors necessitate the development of safer and more effective therapeutic agents. Based on the structures of 4-benzylpiperidine carboxamides and trazodone, arylpiperazine-benzylpiperidines with chemical scaffolds different from those of marketed drugs were designed, synthesized, and evaluated for their neurotransmitter reuptake inhibitory activities. The majority of the synthesized compounds showed greater NE than 5-HT reuptake inhibition. The activities were even greater than those of the standard drug, venlafaxine hydrochloride were. The derivatives with a three-carbon linker showed better activities than the derivatives with a two-carbon linker. Among the newly synthesized compounds, 2d exhibited the strongest reuptake inhibition of the neurotransmitters (IC50 = 0.38 μM for NE and 1.18 μM for 5-HT). The biological activity data demonstrate that arylpiperazine-benzylpiperidines have the potential to be developed as a new class of therapeutic agents to treat neuropsychiatric and neurodegenerative disorders.

Versatile synthesis of disubstituted triazole library for dopamine and serotonin receptor ligands

-

2-[(3-Methoxyphenylethyl)phenoxy]-based ABCB1 inhibitors: Effect of different basic side-chains on their biological properties

Recently, 2-[(3-methoxyphenylethyl)phenoxy]-moiety has been selected for the design and synthesis of new small ABCB1 inhibitors. In the present paper, this moiety has been linked through a spacer of 2-5 carbon atoms to the nitrogen of three different basic nuclei such as: (i) N-4-arylpiperazine, (ii) N-4-methylpiperazine, and (iii) 6,7-dimethoxytetrahydroisoquinoline. The results demonstrated that all the selected basic nuclei were well tolerated and that, globally, the best inhibitory activity for each series was obtained when the spacer between the 2-[(3-methoxyphenylethyl)phenoxy] moiety and the basic nucleus consisted of a four-carbon chain. Among the synthesized compounds, N-4-methylpiperazine- 10c (IC50 = 0-15 μM) and tetrahydroisoquinoline-derivatives 11c (IC50 = 0.08 μM) with the spacer n = 4 for both series, displayed the best potency to inhibit ABCB1 activity. Moreover, for each compound, the ABCB1 interacting mechanism has been evaluated by three combined biological assays. N-4-methylpiperazine- (10a-d) and tetrahydroisoquinoline- (11a-d) derivatives were Cyclosporin A-like ABCB1 nontransported substrates.